Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study

OBJECTIVES: To investigate the efficacy and safety of switching from infliximab reference product (RP) to its biosimilar or maintaining biosimilar treatment in patients with ankylosing spondylitis (AS). METHODS: This open-label extension study recruited patients with AS who completed a 54-week, rand...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Won, Yoo, Dae Hyun, Miranda, Pedro, Brzosko, Marek, Wiland, Piotr, Gutierrez-Ureña, Sergio, Mikazane, Helena, Lee, Yeon-Ah, Smiyan, Svitlana, Lim, Mie-Jin, Kadinov, Vladimir, Abud-Mendoza, Carlos, Kim, HoUng, Lee, Sang Joon, Bae, YunJu, Kim, SuYeon, Braun, Jürgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5284340/
https://www.ncbi.nlm.nih.gov/pubmed/27117698
http://dx.doi.org/10.1136/annrheumdis-2015-208783

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5284340/
https://www.ncbi.nlm.nih.gov/pubmed/27117698
http://dx.doi.org/10.1136/annrheumdis-2015-208783

Ejemplares similares